The Burden of Short-Acting β2-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program
Introduction: Preliminary results from the SABINA (SABA use INAsthma) program showed lower overuse of short-acting β2-agonist (SABA) in Italy compared to other European countries. The aim of the present study was to ascertain whether SABINA’s results might have been affected by the Italian National Health System and pharmaceutical market dynamics, by examining patients’ characteristics in relation to SABA prescription/purchase habits. Methods: Multiple approaches were used: (1) a retrospective study using the General Practitioners’ (GPs) Italian IQVIA Longitudinal Patient Database (LPD) to ass... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Verlag/Hrsg.: |
Adis
|
Schlagwörter: | Asthma / Exacerbation / Guideline recommendation / Primary care / Real-world evidence / SABA consumption / Settore MED/10 - Malattie dell'Apparato Respiratorio |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-29254736 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2434/859140 |